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Abstract The pathogenesis of MS is unknown. In our
studies, we have demonstrated an important role for
citrullinated myelin basic protein (MBP). The accom-
panying loss of positive charge compromises the ability
of MBP to interact with the lipid bilayer. The conver-
sion of arginine to citrulline in brain is carried out by
an enzyme peptidyl arginine deiminase (PAD) 2. The
amount of PAD 2 in brain was increased in MS nor-
mal-appearing white matter. The mechanism respon-
sible for this increase involved hypomethylation of the
promoter region in the PAD 2 gene in MS, but no
change (compared to normal) was found in thymus
tissue DNA from the same MS patients. In addition, no
change was observed in other neurological diseases,
including Alzheimer’s, Parkinson’s, and Huntington’s.
We propose that citrullinated MBP, resulting from
elevated levels of PAD 2 represents an important
biochemical pathway in the pathogenesis of MS.
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Introduction
Demyelinating diseases, such as multiple sclerosis (MS),
the major demyelinating disease of humans affects not
only young adults, but also children. It is the leading
cause of neurological deficit in North America and
Western Europe [1]. It is characterized by the patchy
destruction of the myelin sheath around the axon and is,
therefore, classified as a primary demyelinating disease
[2]. The reason for this patchy destruction is not known.
The MS plaque is characterized by a focal area of myelin
destruction associated with astroglial scar formation.
These lesions are scattered throughout the CNS with a
predilection for optic nerves, brain stem, spinal cord, and
periventricular white matter [3]. Perivascular lympho-
cytic infiltration with macrophages, microglial cells and
astrocytes is a common feature. More recently, it has
been recognized that extensive oligodendrocyte apop-
tosis and myelin macrophages are found in MS tissue,
suggesting a primary neurodegenerative mechanism,
followed by the autoimmune response as a secondary
event [4]. In this type of apoptosis, the cardinal feature is
damage to the most distal part of the oligodendiocyte
process in the periaxonal region [5]. The chemical
changes in myelin that precede this destruction are un-
der intensive investigation. In the present overview, we
suggest that enzymatic changes induced in myelin basic
protein (MBP) may represent an important factor.
The cause of MS is unknown. Two major theories
have emerged: an autoimmune or a neurodegenerative
cause. The autoimmune etiology is considered to arise
from sensitization of T-cells in the periphery by a
mechanism of molecular mimicry, usually involving a
viral antigen with peptide sequences similar to those
found in myelin proteins, especially MBP, a candidate
autoantigen in MS. The neurodegenerative hypothesis
involves metabolic changes in the myelin constituents,
which destabilize the membrane architecture, resulting
in myelin degradation. Since the myelin proteins are
primarily responsible for maintaining the structure of
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the membrane we focused our attention on myelin
proteins, in particular, modifications that are found on
MBP.
Myelin basic protein is an unusual protein. It is a
single protein chain consisting of 170 amino acids.
Since it does not contain cysteine, it cannot form
disulfide bonds. It is a flexible structure, which adapts
to environmental conditions, by changing conforma-
tion. It is a member of a group of proteins considered
to be intrinsically disordered and, therefore, have
considerable conformational flexibility (reviewed
extensively in the contribution of Harauz and Musse in
this issue). A further unusual feature of MBP is the
large number and variety of post-translational modifi-
cations, such as N-terminal acylation, GTP- and ADP-
ribose binding sites, deamidation, methylated arginine,
methionine sulphoxide, phosphorylation, and deimin-
ation of arginyl residues. Citrullination occurs on six
sites in the 18.5 kDa MBP from humans, while phos-
phorylation is found on ten sites at least. These are
summarized in Fig. 1.
One of the modifications, in which we are partic-
ularly interested, involves the conversion of peptide-
bound arginine to peptide bound citrulline, an
enzymatic reaction called deimination. The conver-
sion of arginine to citrulline involves the release of
ammonia. For each arginine converted to citrulline,
one positive charge is lost from the protein. We first
demonstrated that citrulline was present in a crude
MBP fraction from myelin [6]. We then purified the
citrulline containing MBP on CM52 cation exchange
columns essentially as described earlier [7–9]. From
these columns, we obtained a number of fractions, all
of which were MBP. Fractionation of the various
MBPs was shown to be dependent on the net charge
of the highly modified MBP, resulting from phos-
phorylation, deamidation, C-terminal arginine loss,
and others (Fig. 1). The citrullinated MBP was
recovered in the flow-through volume and required
further purification by high-performance liquid
chromatography (HPLC). The purified protein was
sequenced and the arginyl residues that were deimi-
nated were identified. These were R25, R31, R122,
R130, R159, and R169 [10]. This decreased positive
charge affected the ability of the protein to interact
with and organize lipid vesicles. Using liquid X-ray
diffraction, we were able to show that the citrullinated
MBP (termed ‘‘C-8’’ for convenience) was unable to
organize lipid bilayers into compact multilayers,
which was readily achieved by the non-citrullinated
charge isomer (termed C-1, so-called because it
bound most tightly to the CM52 column) [11]. At this
time, we speculated that this failure to organize
bilayers into compact multilayers, may contribute
to myelin instability as seen in MS. These data
demonstrated that the citrullinated MBP had a
limited ability to organize and compact the lipid
bilayers.
Fig. 1 Post-translational modification of MBP. All post-transla-
tional modifications, except methylation of Arg107 (human
sequence), decrease the positive charge. The known modi-
fications are acylation of the N-terminus, GTP binding,
ADP-ribosylation (if R25 is not citrullinated), deamidation,
methionine sulphoxide, mono, and dimethylation of Arg107,
phosphorylation at Ser/Thr residues and Tyr and deimination
of arginyl residues (six sites in the 18.5 kDa MBP from normal
brain). The structure, shown as a hairpin, occurs at the tri-proline
region at the site of the bend. The figure was adapted and
modified from Moscarello (1990, Myelin basic protein: a
dynamically changing structure. In: Dynamic interactions of
myelin proteins, George Hashim and Mario Moscarello (eds)
Prog Clin Bio Res, vol 336)
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The citrullinated MBP was isolated from white
matter of MS brain and compared to that isolated from
normal brain. We reported that the relative amount of
the citrullinated MBP was increased in MBP isolated
from MS brain. Whereas, it accounted for 20% of the
MBP isolated from normal brain, a threefold increase
was found in chronic MS. Thus, the ratio of citrulli-
nated MBP/non-citrullinated MBP was 0.82 in the
normal and it was 2.45 in the MS MBP [12]. In a single
case of Marburg’s disease (a fulminating form of MS),
80–90% of the MBP was citrullinated, with a citrulli-
nated MBP/non-citrullinated MBP ratio of 6.7 [13, 14].
Therefore, MBP in Marburg’s type of MS was almost
totally deiminated. Citrullination of MBP has been
reported to diminish charge density, which diminishes
its interaction with lipids, making it more vulnerable to
proteolytic attack [15].
The effects of deimination on protein structure and
protein-lipid interactions in myelin are diverse and
have been thoroughly reviewed [16]. Briefly, deimina-
tion of MBP alters the 3D structure of MBP, producing
a more open conformation. The more open confor-
mation of MBP increases its susceptibility to proteases
such as cathepsin D, a myelin associated protease.
MBP containing six citrullinyl residues is digested four
times faster than non-deiminated MBP. The MBP
containing 18 citrullinyl residues was digested 45 times
faster than MBP from normal brain. These data
support the view that deimination of MBP not only
decreases the positive charge on the molecule, but also
creates a more open structure [17].
These perturbations in structure affect the interac-
tions of the protein with the lipid bilayer and decrease
the compaction of the multilayer structure of myelin.
The deiminated protein had a reduced ability to bind
and aggregate lipid vesicles and the highly deiminated
form of MBP caused fragmentation of lipid vesicles
[18], a process which may have implications for myelin
breakdown in MS.
Electrostatic interactions between the negatively
charged phospholipids and the positively charged
amino acids (Arg and Lys) are the origin of attraction
of MBP to the lipid. MBP is postulated to work as a
glue for adjacent bilayers [19, 20] by binding to the
polar head groups. This mechanism of interaction is
interfered with by deimination of arginyl residues,
since the resulting citrulline carries a neutral charge.
The conversion of arginine ﬁ citrulline in proteins
is carried out by the enzyme peptidyl arginine dei-
minase (PAD). Of the five known PAD enzymes, PAD
2 is the one involved in the deimination of MBP. Since
our studies on the deiminated MBP in humans was
obtained from autopsy material, the question of the
origins of the citrullinated protein, as possibly
artefactual, was addressed. To resolve this issue, we
explored the temporal relationship between the
appearance of the citrullinated protein and the
up-regulation of the PAD 2 enzyme, which could only
be done in a relevant animal model. Such a model was
available to us. It is a transgenic model, containing 70
copies of the transgene for the myelin proteolipid
protein DM20. This mouse is normal for the first
3 months of its life and then demyelinates spontane-
ously. We measured PAD enzyme and citrullinated
MBP. We found that PAD 2 was up-regulated at
2 months of age and citrullinated MBP at 3 months of
age, suggesting a precursor-product type relationship
[21]. We postulated that up-regulation of PAD 2 was
the primary response. To substantiate this hypothesis, a
thorough study was carried out on PAD 2 regulation.
In this regard, we have reported that paclitaxel
(Taxol) inhibited the activity of purified PAD 2 iso-
lated from bovine brain in an in vitro assay [22]. In in
vivo studies, we demonstrated that paclitaxel attenu-
ated clinical disease in the spontaneously demyelinat-
ing mouse model described above [23]. In a recently
submitted manuscript, we extended our Taxol studies
further by demonstrating that the addition of the me-
thyl donor, vitamin B12, suppressed both immune and
non-immune demyelinating disease in mice (F. G.
Mastronardi et al. 2006, submitted data), better than
paclitaxel alone. These data suggest that drugs, which
target PAD 2, in the presence of a methyl donor, such
as vitamin B12, may be beneficial in demyelinating
disease.
Another PAD enzyme, PAD 4, has been implicated
in the pathogenesis of psoriasis [24], rheumatoid
arthritis [25, 26] and MS (F. G. Mastronardi et al. 2006,
submitted data). PAD 4 is different from other PAD
enzymes, because the gene contains a nuclear locali-
zation signal (PPAKKKST) [27], not present in any of
the other PAD enzymes. Translocation of the enzyme
from the cytoplasm to the nucleus, has been shown to
involve the cytokine tumor necrosis factor a (TNFa).
The substrate for PAD 4 in the nucleus is histone
(F. G. Mastronardi et al. 2006, submitted data). Dei-
mination of arginyl residues of histones decreases the
positive charge on histone, which compromises its
ability to interact with DNA, possibly resulting in
apoptosis of oligodendrocytes. On the other hand,
deacetylation of histones would increase the positive
charge on histone. Therefore, these two processes, the
deimination of arginyl residues and the deacetylation
of lysyl residues of histones affect the positive charge
on histone in opposite ways, and these two processes
may have a regulatory function.
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Since we determined that up-regulation of PAD 2,
preceded demyelination in the animal model, we
searched for the mechanism responsible. An exami-
nation of the nucleotide sequence of the PAD 2 pro-
moter revealed that it was high in CpG sequences.
CpG sequences are important, because cytosine is a
target for methylation by DNA methyltransferase,
which produces 5-methylcytosine. Methylation of the
promoter region of a gene silences the gene, whereas
demethylation increases transcription.
Accordingly, we isolated DNA from white matter
obtained from normal individuals and patients who
died with MS. The DNA was treated with bisulphite to
convert cytosine into uracil. The methylcytosine is not
affected by bisulphite. We found that methylcytosine
accounted for less than 4% of the cytosines in the PAD
2 promoter in MS (n = 17), whereas in the normal, the
methylcytosine in the PAD 2 promoter was 12%
(n = 8). Therefore, the PAD 2 promoter was hy-
pomethylated in the DNA from MS white matter
samples. DNA was also obtained from thymus of the
same MS patients. The amount of methylcytosine was
the same in both MS and normal samples. Therefore,
the hypomethylation found in MS appeared to be tis-
sue specific. When we examined other neurological
diseases, including Alzheimer’s, Parkinson’s, and
Huntington’s, the amounts of methylcytosine were the
same as normal (Mastronardi et al. 2006 in prepara-
tion). Therefore, the hypomethylation of the PAD 2
promoter was unique to MS brain. This hypomethyla-
tion of the promoter of PAD 2 may account for the
increase in PAD 2 in MS brain (summarized in Fig. 2).
The removal of methyl groups from methylcytosine
in CpG sequences is carried out by a DNA demethy-
lase. We proposed that up-regulation of the demethy-
lase may account for the hypomethylation state of
the PAD 2 promoter in MS. When we measured the
total demethylase activity in brain homogenates from
normal and MS white matter, using a synthetic meth-
ylcytosine-guanosine (CpG) substrate [28] we demon-
strated that the enzyme in NAWM from MS brain
was increased twofold over normal, suggesting the
DNA demethylase may have an important role in the
hypomethylation of the PAD 2 promoter. Therefore,
the hypomethylated state of the PAD 2 promoter may
involve up-regulation of the DNA demethylase at least
in part.
As a result of the work summarized in this overview,
we postulate the following sequence of events during
the pathogenesis of MS. The citrullinated MBP, be-
cause of its decreased positive charge, prevents proper
compaction of the bilayer, so that the multilamellar
structure is less stable. Since PAD 2 has been shown to
be present in myelin by immunogold electron micros-
copy (unpublished results), the conversion of non-cit-
rullinated to citrullinated MBP can occur locally in
myelin. Preliminary results have shown that immuno-
gold labeling of PAD 2 in mouse optic nerve was not
random, but was found in clusters in the axon itself and
in the myelin sheath. In the latter, the clusters were
found mainly at the junction of the myelin sheath and
the axon (periaxonal) with some gold particles dis-
tributed in the myelin sheath. The presence of the
PAD 2 enzyme at these sites suggests that the citrul-
linated MBP would be formed in these clusters in
myelin, eventually resulting in plaques.
When we examined the extent of labeling in the
optic nerve of the spontaneously demyelinating trans-
genic mouse, we found a threefold increase in the
number of gold particles. This increase in PAD 2
labeling demonstrated that increased amounts of PAD
2 were present in the transgenic mouse, accounting for
an increase in the citrullinated MBP. Since citrulli-
nated MBP is present in the normal myelin sheath
(20% of the total MBP), citrullinated MBP can be
tolerated to this extent. However, increased amounts
as found in chronic MS (threefold), and in fulminating
MS (six to sevenfold), cannot be accommodated in a
compact myelin sheath, resulting in destabilization.
Peptidyl arginine deiminase 2 has been reported
recently to be elevated in primary open-angle glau-
coma, where it was considered responsible for the
deimination of several optic nerve proteins, in addition
to MBP. Concomitant with this protein deimination, a
decrease in arginine methylation was also observed
[29]. Therefore, the PAD 2 enzymes have important
roles in several nervous system diseases.
Oligodendrocyte apoptosis has been reported in MS
white matter in the absence of lymphocytes or myelin
phagocytes [4]. The major feature of this type of injury
is damage to the most distal part of the oligodendro-
cyte process (periaxonal), which results in clumping of
proteins [5], followed by apoptosis. The possible role of
the PAD 2 enzyme in this process has not yet been
demonstrated. If it can be established that protein
deimination at sites of PAD 2 clusters does occur, it
may suggest that demyelination begins in the periaxo-
nal myelin sheath and subsequently moves outward.
Although this hypothesis is speculative, it warrants
investigation. The increased amount of PAD 2 in MS
white matter probably reflects a greater production of
the enzyme. Since the PAD 2 promoter is rich in CpG
islands, we showed that the promoter was hypome-
thylated. These studies are ongoing in our laboratory.
They suggest immediately that the reversal of the hy-
pomethylated state may be a therapeutic target in MS.
254 Neurochem Res (2007) 32:251–256
123
The importance of methylation in a therapeutic
strategy of MS has been suggested by us recently [(F.
G. Mastronardi et al. 2006, submitted data), 30]. In
these studies, we demonstrated that vitamin B12 in
combination with either interferon b or paclitaxel,
effectively ameliorated demyelinating disease in both
EAE and non-immune demyelinating disease. In a
detailed mass spectrophotometric study of the various
components of MBP, we showed arginine methylation
was decreased in most of the components of the MBPs
from MS material [31], supporting the view that defects
in methylation may involve protein methylation as
well. The methylation process requires Vitamin B12,
which transfers its methyl group to homocyteine syn-
thesizing methionine, which is then converted to S-
adenosytmethionine, the methyl donor in all biological
methylation reactions, including methylation of cyto-
sine in DNA to methylcytosine. These studies with the
preliminary studies reported above suggest an impor-
tant role for methylation/demethylation reactions in
the pathogenesis of MS.
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